Matrix metalloproteinase inhibitors

Current Oncology Reports

Volumn 6, Issue 2, 2004, Pages 96-102

  Ramnath, Nithya ^a   Creaven, Patrick J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; BATIMASTAT; CARBOPLATIN; DOXYCYCLINE; GEMCITABINE; HALOFUGINONE; HYDROXAMIC ACID DERIVATIVE; MANUMYCIN A; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PLACEBO; PLASMIN INHIBITOR; PREDNISONE; PRINOMASTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE; REBIMASTAT; RIBOZYME; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ANEMIA; ARTHRITIS; ASCITES; BONE PAIN; CANCER INVASION; CANCER STAGING; CARCINOGENIC ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DESIGN; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FATIGUE; HUMAN; IMMUNITY; IMMUNOREGULATION; JAUNDICE; KAPOSI SARCOMA; METASTASIS; MYALGIA; NAUSEA; POLYARTHRITIS; REVIEW; STOMACH CANCER; VOMITING; WEIGHT REDUCTION; DRUG ANTAGONISM; GENETICS; METABOLISM; NEOPLASM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASMS; PROTEASE INHIBITORS; TREATMENT OUTCOME;

EID: 2342637653     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-004-0020-7     Document Type: Review

References (50)

1. Fini ME, Cook JR, Mohan R, et al.: Regulation of matrix metalloproteinase gene expression. In Matrix Metalloproteinases. Edited by Parks WC, Mecham RP. San Diego: Academic Press; 1998:299-356.
2. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 2003, 92:827-839.
3. Bissell MJ, Radisky D: Putting tumors in context. Nat Rev Cancer 2001, 1:46-54.
4. Sternlicht MD, Lochter A, Sympson CJ, et al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
5. D'Armiento J, DiColandrea T, Dalai SS, et al.: Collagenase expression in transgenic mouse skin causes hyperkeratosis and acanthosis and increases susceptibility to tumorigenesis. Mol Cell Biol 1995, 15:5732-5739.
6. Bannikov GA, Karelina TV, Collier IE, et al.: Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J Biol Chem 2002, 277:16022-16027.
7. Knäuper V, Will H, López-Otin C, et al.: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. J Biol Chem 1996, 271:17124-17131.
8. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283.
9. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
10. Park M-J, Kim M-S, Park I-C, et al.: PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res 2002, 62:6318-6322.
11. Koul D, Parthasarathy R, Shen R, et al.: Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 2001, 20:6669-6678.
12. Johansson N, Ala-aho R, Uitto V-J, et al.: Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen activated protein kinase. J Cell Sci 2000, 113:227-235.
13. Lakka SS, Jasti SL, Gondi C, et al.: Downregulation of MMP-9 in ERK-mutated stable transfectants. Oncogene 2002, 21:5601-5608.
14. Zhang Y, Thant AA, Machida K, et al.: Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 2002, 62:3962-3965.
15. Hua J, Muschel RJ: Inhibition of matrix metalloproteinase-9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996, 56:5279-5284.
16. Kondraganti S, Mohanam S, Chintala SK, et al.: Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000, 60:6851-6855.
17. Lund LR, Rømer J, Bugge TH, et al.: Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999, 18:4645-4656.
18. Betz M, Huxley P, Davies SJ, Mushtaq et al.: 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with distinct selectivity profile. Eur J Biochem 1997, 247:356-363.
19. Wojtowicz-Praja S, Low J, Marshall J, et al.: Phase 1 trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 1996, 14:193-202.
20. Macaulay VM, O'Byrne KJ, Saunders MP, et al.: Phase 1 study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999, 5:513-520.
21. Beattie GJ, Smyth JF: Phase 1 study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998, 4:1899-1902.
22. Nemunaitis J, Poole C, Primrose J, et al.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998, 4:1101-1109.
23. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
24. Bramhall SR, Hallissey MT, Whiting J, et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002, 86:1864-1870.
25. Coussens LM, Fingleton B, Matrisian LM: Matrix Metalloproteinase inhibitors and cancer: trials and tribulations [review]. Science 2002, 295:2387-2392.
26. Rowinsky EK, Humphrey R, Hammond LA, M et al.: Phase 1 and pharmacologic study of the specific matrix metalloproteinase inhibitor Bay 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol 2000, 18:178-186.
27. Goel R, Hirte H, Major P, et al.: Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients [abstract]. Proc ASCO 1999, 18:160a.
28. Erlichman C, Adjei A, Alberts S, et al.: Phase 1 study of BAY 12-9566: a matrix metalloproteinase inhibitor (MMPI) [abstract]. Proc ASCO 1998, 17:217a.
29. Grochow L, O'Reilly S, Humphrey R, et al.: Phase 1 and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY 12-9566 [abstract]. Proc ASCO 1998, 17:213a.
30. Tolcher A, Rowinsky EK, Rizzo J, et al.: A phase 1 and pharmacokinetic study of the oral matrix metalloproteinase inhibitor Bay 12-9566 in combination with paclitaxel and carboplatin [abstract]. Proc ASCO 1999, 18:160.
31. Moore M, Hamm J, Eisenberg P, et al.: A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer [abstract]. Proc ASCO 2000, 19:240a.
32. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
33. Hande K, Wilding G, Ripple et al.: Phase 1 study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patient having advance cancer [abstract]. Ann Oncol 1998, 9:74.
34. Wilding G, Small E, Ripple G, et al.: Phase 1 study of AG3340, a matrix metalloprotease inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancer [abstract]. Ann Oncol 1998, 9:74.
35. D'Olimpio J, Hande K, Collier M, et al.: Phase 1 study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors [abstract]. Proc ASCO 1999, 18:160.
36. Poulaki V: BMS-275291 Bristol-Myers Squibb. Curr Opin Investig Drugs 2002, 3:500-504.
37. Levitt NC, Eskens F, Proper DJ, et al.: A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor [abstract]. Proc ASCO 1998, 17:213.
38. Mant TGK, Bradford DBA, Amin DM, et al.: A phase 1, double-blind, randomized, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetic profile of S-3304, a matrix metalloproteinase inhibitor, when given in multiple doses with high doses for 4 weeks to healthy volunteers [abstract]. Eur J Cancer 2002, 38:S81.
39. Yoshioka T, Watanabe F, Tsuzuki H, et al.: In vitro pharmacological profiles and in vivo anti-angiogenesis activity of S-3304, a novel matrix metalloproteinase inhibitor [abstract]. Eur J Cancer 2002, 38:S81.
40. Creaven PJ, Sullivan DM, Eckhardt G, et al.: A phase I study of S-3304 a matrix metalloproteinases inhibitor in patients with solid tumors [abstract]. Eur J Cancer 2002, 38:S77.
41. Dupont E, Brazeau P, Juneau C: Extracts of shark cartilage having an antiangiogenic activity and an effect on tumor progression: process of making thereof. United States Patent #5 1995, 618:925.
42. Gringas D, Renaud A, Mousseau N, et al.: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001, 21:145-156.
43. Batist G, Patenaude F, Champage P, et al.: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002, 13:1259-1263.
44. Gordon MS, Battiato LA, Jones D, et al.: A phase 1 trial of doxycycline (Doxy) in patients with caner [abstract]. Proc ASCO 1997, 16:226.
45. Rudek MA, Figg WD, Dyer V, et al.: Phase 1 clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 2001, 19:584-592.
46. Cianfrocca M, Cooley TP, Lee JY, et al.: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002, 20(1):153-159.
47. Clinical Trials: Linking Patients to Medical Research. http://www.clinicaltrials.gov/ct. Accessed June 23, 2003.
48. Stearns ME, Wang M: Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis 1998, 16:693-702.
49. Liotta LA, Tryggvason K, Garbisa S, et al.: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284:67-68.
50. López-Otín C, Overall C: Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002, 3:509-519.